Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment
Background. Anastrozole has been approved for treatment of hormone receptor-positive advanced or metastatic breast cancer by FDA. This study was to assess Anastrozole-related adverse events (AEs) of real-world through data mining of the US Food and drug administration adverse event reporting system...
Saved in:
| Main Authors: | Jie Li, Bin Zhao, YongQing Zhu, Jibiao Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | International Journal of Clinical Practice |
| Online Access: | http://dx.doi.org/10.1155/2024/5132916 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selective estrogen receptor modulators and aromatase inhibitors in the treatment of functional male hypogonadism
by: Jakub Wydra, et al.
Published: (2025-08-01) -
Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
by: Adam M. Brufsky, et al.
Published: (2025-04-01) -
Aromatase Inhibitors and Dementia Risk: Putting Safety Into Perspective
by: Mariam Rizk, et al.
Published: (2025-06-01) -
Case Report of a Woman With Anastrozole-Associated Radiation Recall
by: Parisa Shamsesfandabadi, MD, et al.
Published: (2025-01-01) -
Aromatase Inhibitor-Related Lower Limb Tendinopathies: Ultrasound is on the Agenda
by: Berkay Yalçınkaya, et al.
Published: (2025-07-01)